English | Español

Abbvie
Press release submission | Jul 24, 2021

DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients

Press release submission | Aug 15, 2020

ABBVIE: New England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients
Press release submission | Nov 26, 2018

ABBVIE: Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy
Press release submission | Sep 23, 2018

ABBVIE: Announces $5 Million Donation to Family Reach to Support Children Battling Cancer and Their Families
Carrie Bradon | Nov 28, 2017

AbbVie to take part in Evercore ISI Biopharma Catalyst conference
Kathy Adams | Nov 15, 2017

AbbVie executive to present at Jefferies London Healthcare Conference
Robert Hadley | Nov 7, 2017

FDA fast-tracking review for AbbVie’s endometriosis drug
Mark Iandolo | Nov 1, 2017

AbbVie to present abstracts on its investigational immunology medicine portfolio

Trending
+ Regulatory
Patient Daily News Service | Dec 15, 2024

Steve Forbes: ‘Unfair’ to allow ‘big insurer-PBMs to pocket big Rx discounts meant for patients’
+ Pharmaceuticals
Patient Daily | Dec 17, 2024

Lung association warns against combined risks of smoking and radon
Patient Daily reports | Dec 13, 2024

Unicycive CEO Dr. Gupta: 'I started Unicycive to address the significant challenges in healthcare'
+ Pharmaceuticals
Patient Daily | Dec 20, 2024

Discovery of replication hubs may lead to new antiviral therapies for norovirus